Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| COGNITION THERAPEUTICS INCCGTX · Entity 6792 | Director | October 13, 2021 | October 16, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
COGNITION THERAPEUTICS INC
Report date October 13, 2021 · Filed October 16, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Breedlove Family Limited Partnership. | 44,806 |
Reported balance
After 2021-10-13 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2021-10-13 · Conversion · Acquired 44,806 · Balance 44,806 F1: The Series A-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. F7: Represents securities held by the Breedlove Family Limited Partnership. The reporting person, as general partner of the Breedlove Family Limited Partnership, may be deemed to beneficially own the reported securities indirectly, but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Breedlove Family Limited Partnership. | 81,520 |
Reported balance
After 2021-10-13 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2021-10-13 · Conversion · Acquired 36,714 · Balance 81,520 F2: The Series A-2 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. F7: Represents securities held by the Breedlove Family Limited Partnership. The reporting person, as general partner of the Breedlove Family Limited Partnership, may be deemed to beneficially own the reported securities indirectly, but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Breedlove Family Limited Partnership. | 306,801 |
Reported balance
After 2021-10-13 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2021-10-13 · Conversion · Acquired 225,281 · Balance 306,801 F3: The Series B Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. F7: Represents securities held by the Breedlove Family Limited Partnership. The reporting person, as general partner of the Breedlove Family Limited Partnership, may be deemed to beneficially own the reported securities indirectly, but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Breedlove Family Limited Partnership. | 400,097 |
Reported balance
After 2021-10-13 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2021-10-13 · Conversion · Acquired 93,296 · Balance 400,097 F4: The Series B-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. F7: Represents securities held by the Breedlove Family Limited Partnership. The reporting person, as general partner of the Breedlove Family Limited Partnership, may be deemed to beneficially own the reported securities indirectly, but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Breedlove Family Limited Partnership. | 404,451 |
Reported balance
After 2021-10-13 transaction · row 6
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 6 · 2021-10-13 · Conversion · Acquired 4,354 · Balance 404,451 F7: Represents securities held by the Breedlove Family Limited Partnership. The reporting person, as general partner of the Breedlove Family Limited Partnership, may be deemed to beneficially own the reported securities indirectly, but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Breedlove Family Limited Partnership. | 404,439 |
Reported balance
After 2021-10-13 transaction · row 7
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 7 · 2021-10-13 · Sale · Disposed 11.74 · Balance 404,439 F5: On October 13, 2021, the reporting person exercised a warrant to purchase 4,354 shares of CGTX common stock for $0.032 per share. The reporting person paid the exercise price on a cashless basis, resulting in CGTX's withholding of 11.74 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 4,342 shares. The issuer paid cash to the reporting person in lieu of any fractional share amounts. F7: Represents securities held by the Breedlove Family Limited Partnership. The reporting person, as general partner of the Breedlove Family Limited Partnership, may be deemed to beneficially own the reported securities indirectly, but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. |
| Series A-1 Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectBy Breedlove Family Limited Partnership. | 0 |
Reported balance
After 2021-10-13 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-10-13 · Conversion · Disposed 144,928 · Balance 0 F1: The Series A-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. F7: Represents securities held by the Breedlove Family Limited Partnership. The reporting person, as general partner of the Breedlove Family Limited Partnership, may be deemed to beneficially own the reported securities indirectly, but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. |
| Series A-2 Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectBy Breedlove Family Limited Partnership. | 0 |
Reported balance
After 2021-10-13 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2021-10-13 · Conversion · Disposed 118,835 · Balance 0 F2: The Series A-2 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. F7: Represents securities held by the Breedlove Family Limited Partnership. The reporting person, as general partner of the Breedlove Family Limited Partnership, may be deemed to beneficially own the reported securities indirectly, but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. |
| Series B Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectBy Breedlove Family Limited Partnership. | 0 |
Reported balance
After 2021-10-13 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2021-10-13 · Conversion · Disposed 826,278 · Balance 0 F3: The Series B Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. F7: Represents securities held by the Breedlove Family Limited Partnership. The reporting person, as general partner of the Breedlove Family Limited Partnership, may be deemed to beneficially own the reported securities indirectly, but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. |
| Series B-1 Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectBy Breedlove Family Limited Partnership. | 0 |
Reported balance
After 2021-10-13 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2021-10-13 · Conversion · Disposed 301,978 · Balance 0 F4: The Series B-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. F7: Represents securities held by the Breedlove Family Limited Partnership. The reporting person, as general partner of the Breedlove Family Limited Partnership, may be deemed to beneficially own the reported securities indirectly, but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. |
| Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.03 · Expires 2023-03-15 | IndirectBy Breedlove Family Limited Partnership. | 0 |
Reported balance
After 2021-10-13 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2021-10-13 · Other · Disposed 4,354 · Balance 0 F6: The warrant expries on the earliest of (i) March 15, 2023, (ii) upon a liquidation, dissolution or winding up of the Company, (iii) the closing of a Sale Transaction (as defined in the warrant), (iv) upon the closing of the Issuer's initial public offering, or (v) upon repayment of a promissory note issued in connection with the warrant. F7: Represents securities held by the Breedlove Family Limited Partnership. The reporting person, as general partner of the Breedlove Family Limited Partnership, may be deemed to beneficially own the reported securities indirectly, but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 7,611 |
Reported balance
Holding disclosure · report date 2021-10-13 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 7,611 |
Filing footnotes · ownership attribution and instrument terms
F1: The Series A-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration.
F2: The Series A-2 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration.
F3: The Series B Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration.
F4: The Series B-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration.
F5: On October 13, 2021, the reporting person exercised a warrant to purchase 4,354 shares of CGTX common stock for $0.032 per share. The reporting person paid the exercise price on a cashless basis, resulting in CGTX's withholding of 11.74 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 4,342 shares. The issuer paid cash to the reporting person in lieu of any fractional share amounts.
F6: The warrant expries on the earliest of (i) March 15, 2023, (ii) upon a liquidation, dissolution or winding up of the Company, (iii) the closing of a Sale Transaction (as defined in the warrant), (iv) upon the closing of the Issuer's initial public offering, or (v) upon repayment of a promissory note issued in connection with the warrant.
F7: Represents securities held by the Breedlove Family Limited Partnership. The reporting person, as general partner of the Breedlove Family Limited Partnership, may be deemed to beneficially own the reported securities indirectly, but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 13, 2021 Filed Oct 16, 2021 01:02 UTC | COGNITION THERAPEUTICS INC CGTX · Entity 6792 | OtherWarrant (Right to Buy) · Derivative | 4,354 | $0.00 Strike: $0.03 | $0.00 |
DisclosureSEC source: 0001104659-21-126894 · tm2130061-4_4seq1.xml · derivative · entry 12 Breedlove Mark H. · CIK 0001876529 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Breedlove Family Limited Partnership. Disclosed balance after: 0 Underlying: Common Stock · 4,354 shares Expires 2023-03-15 F6 · derivative.exercise_date: The warrant expries on the earliest of (i) March 15, 2023, (ii) upon a liquidation, dissolution or winding up of the Company, (iii) the closing of a Sale Transaction (as defined in the warrant), (iv) upon the closing of the Issuer's initial public offering, or (v) upon repayment of a promissory note issued in connection with the warrant. F6 · derivative.expiration_date: The warrant expries on the earliest of (i) March 15, 2023, (ii) upon a liquidation, dissolution or winding up of the Company, (iii) the closing of a Sale Transaction (as defined in the warrant), (iv) upon the closing of the Issuer's initial public offering, or (v) upon repayment of a promissory note issued in connection with the warrant. F7 · ownership.nature: Represents securities held by the Breedlove Family Limited Partnership. The reporting person, as general partner of the Breedlove Family Limited Partnership, may be deemed to beneficially own the reported securities indirectly, but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| October 13, 2021 Filed Oct 16, 2021 01:02 UTC | COGNITION THERAPEUTICS INC CGTX · Entity 6792 | ConversionSeries B-1 Convertible Preferred Stock · Derivative | 301,978 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-126894 · tm2130061-4_4seq1.xml · derivative · entry 11 Breedlove Mark H. · CIK 0001876529 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Breedlove Family Limited Partnership. Disclosed balance after: 0 Underlying: Common Stock · 93,296 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The Series B-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. F4 · derivative.exercise_date: The Series B-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. F4 · derivative.expiration_date: The Series B-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. F7 · ownership.nature: Represents securities held by the Breedlove Family Limited Partnership. The reporting person, as general partner of the Breedlove Family Limited Partnership, may be deemed to beneficially own the reported securities indirectly, but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| October 13, 2021 Filed Oct 16, 2021 01:02 UTC | COGNITION THERAPEUTICS INC CGTX · Entity 6792 | ConversionSeries B Convertible Preferred Stock · Derivative | 826,278 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-126894 · tm2130061-4_4seq1.xml · derivative · entry 10 Breedlove Mark H. · CIK 0001876529 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Breedlove Family Limited Partnership. Disclosed balance after: 0 Underlying: Common Stock · 225,281 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The Series B Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. F3 · derivative.exercise_date: The Series B Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. F3 · derivative.expiration_date: The Series B Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. F7 · ownership.nature: Represents securities held by the Breedlove Family Limited Partnership. The reporting person, as general partner of the Breedlove Family Limited Partnership, may be deemed to beneficially own the reported securities indirectly, but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| October 13, 2021 Filed Oct 16, 2021 01:02 UTC | COGNITION THERAPEUTICS INC CGTX · Entity 6792 | ConversionSeries A-2 Convertible Preferred Stock · Derivative | 118,835 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-126894 · tm2130061-4_4seq1.xml · derivative · entry 9 Breedlove Mark H. · CIK 0001876529 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Breedlove Family Limited Partnership. Disclosed balance after: 0 Underlying: Common Stock · 36,714 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Series A-2 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. F2 · derivative.exercise_date: The Series A-2 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. F2 · derivative.expiration_date: The Series A-2 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. F7 · ownership.nature: Represents securities held by the Breedlove Family Limited Partnership. The reporting person, as general partner of the Breedlove Family Limited Partnership, may be deemed to beneficially own the reported securities indirectly, but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| October 13, 2021 Filed Oct 16, 2021 01:02 UTC | COGNITION THERAPEUTICS INC CGTX · Entity 6792 | ConversionSeries A-1 Convertible Preferred Stock · Derivative | 144,928 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-126894 · tm2130061-4_4seq1.xml · derivative · entry 8 Breedlove Mark H. · CIK 0001876529 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Breedlove Family Limited Partnership. Disclosed balance after: 0 Underlying: Common Stock · 44,806 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. F1 · derivative.exercise_date: The Series A-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. F1 · derivative.expiration_date: The Series A-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. F7 · ownership.nature: Represents securities held by the Breedlove Family Limited Partnership. The reporting person, as general partner of the Breedlove Family Limited Partnership, may be deemed to beneficially own the reported securities indirectly, but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| October 13, 2021 Filed Oct 16, 2021 01:02 UTC | COGNITION THERAPEUTICS INC CGTX · Entity 6792 | SaleCommon Stock | 11.74 | $12.00 | $140.88 |
DisclosureSEC source: 0001104659-21-126894 · tm2130061-4_4seq1.xml · nonDerivative · entry 7 Breedlove Mark H. · CIK 0001876529 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Breedlove Family Limited Partnership. Disclosed balance after: 404,439 F5 · kind: On October 13, 2021, the reporting person exercised a warrant to purchase 4,354 shares of CGTX common stock for $0.032 per share. The reporting person paid the exercise price on a cashless basis, resulting in CGTX's withholding of 11.74 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 4,342 shares. The issuer paid cash to the reporting person in lieu of any fractional share amounts. F7 · ownership.nature: Represents securities held by the Breedlove Family Limited Partnership. The reporting person, as general partner of the Breedlove Family Limited Partnership, may be deemed to beneficially own the reported securities indirectly, but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| October 13, 2021 Filed Oct 16, 2021 01:02 UTC | COGNITION THERAPEUTICS INC CGTX · Entity 6792 | ConversionCommon Stock | 4,354 | $0.03 | $139.33 |
DisclosureSEC source: 0001104659-21-126894 · tm2130061-4_4seq1.xml · nonDerivative · entry 6 Breedlove Mark H. · CIK 0001876529 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Breedlove Family Limited Partnership. Disclosed balance after: 404,451 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · ownership.nature: Represents securities held by the Breedlove Family Limited Partnership. The reporting person, as general partner of the Breedlove Family Limited Partnership, may be deemed to beneficially own the reported securities indirectly, but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| October 13, 2021 Filed Oct 16, 2021 01:02 UTC | COGNITION THERAPEUTICS INC CGTX · Entity 6792 | ConversionCommon Stock | 93,296 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-126894 · tm2130061-4_4seq1.xml · nonDerivative · entry 5 Breedlove Mark H. · CIK 0001876529 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Breedlove Family Limited Partnership. Disclosed balance after: 400,097 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: The Series B-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. F7 · ownership.nature: Represents securities held by the Breedlove Family Limited Partnership. The reporting person, as general partner of the Breedlove Family Limited Partnership, may be deemed to beneficially own the reported securities indirectly, but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| October 13, 2021 Filed Oct 16, 2021 01:02 UTC | COGNITION THERAPEUTICS INC CGTX · Entity 6792 | ConversionCommon Stock | 225,281 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-126894 · tm2130061-4_4seq1.xml · nonDerivative · entry 4 Breedlove Mark H. · CIK 0001876529 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Breedlove Family Limited Partnership. Disclosed balance after: 306,801 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: The Series B Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. F7 · ownership.nature: Represents securities held by the Breedlove Family Limited Partnership. The reporting person, as general partner of the Breedlove Family Limited Partnership, may be deemed to beneficially own the reported securities indirectly, but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| October 13, 2021 Filed Oct 16, 2021 01:02 UTC | COGNITION THERAPEUTICS INC CGTX · Entity 6792 | ConversionCommon Stock | 36,714 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-126894 · tm2130061-4_4seq1.xml · nonDerivative · entry 3 Breedlove Mark H. · CIK 0001876529 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Breedlove Family Limited Partnership. Disclosed balance after: 81,520 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The Series A-2 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. F7 · ownership.nature: Represents securities held by the Breedlove Family Limited Partnership. The reporting person, as general partner of the Breedlove Family Limited Partnership, may be deemed to beneficially own the reported securities indirectly, but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| October 13, 2021 Filed Oct 16, 2021 01:02 UTC | COGNITION THERAPEUTICS INC CGTX · Entity 6792 | ConversionCommon Stock | 44,806 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-126894 · tm2130061-4_4seq1.xml · nonDerivative · entry 2 Breedlove Mark H. · CIK 0001876529 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Breedlove Family Limited Partnership. Disclosed balance after: 44,806 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. F7 · ownership.nature: Represents securities held by the Breedlove Family Limited Partnership. The reporting person, as general partner of the Breedlove Family Limited Partnership, may be deemed to beneficially own the reported securities indirectly, but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.